- Home
- RGA vs JAZZ Comparison
RGA vs JAZZ Comparison
Compare RGA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGA | JAZZ |
|---|---|---|
| Founded | 1973 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 16.1B |
| IPO Year | 1996 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RGA | JAZZ |
|---|---|---|
| Price | $256.09 | $223.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 22 |
| Target Price | $277.56 | ★ $294.36 |
| AVG Volume (30 Days) | 309.7K | ★ 637.6K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 64.86 | N/A |
| EPS | ★ 11.99 | 7.17 |
| Revenue | ★ $23,698,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $13.98 | $10.59 |
| Revenue Next Year | $4.59 | $5.91 |
| P/E Ratio | ★ $21.35 | $31.03 |
| Revenue Growth | ★ 7.20 | N/A |
| 52 Week Low | $178.21 | $128.80 |
| 52 Week High | $258.53 | $266.38 |
Technical Indicators
Market Signals| Indicator | RGA | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 65.47 | 31.33 |
| Support Level | $241.85 | $222.49 |
| Resistance Level | N/A | $242.66 |
| Average True Range (ATR) | 5.27 | 6.51 |
| MACD | 0.58 | -0.94 |
| Stochastic Oscillator | 97.96 | 28.24 |
Price Performance
Historical ComparisonAbout RGA Reinsurance Group of America Incorporated
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.